
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics is experiencing positive developments indicated by a recent increase in their target price, now set at $46, driven by higher net cash and a reduced share count. The company’s clinical pipeline, particularly with the advancements in DNTH103, shows promise in differentiating their product offerings in the competitive landscape of complement therapeutics. As the company progresses in its clinical trials, there is an overall positive sentiment regarding its capabilities to address severe autoimmune and inflammatory diseases, reinforcing a favorable outlook for its financial trajectory.
Bears say
Dianthus Therapeutics Inc. may face significant challenges in advancing its pipeline due to potential funding shortfalls that could hinder its operations. The company has removed an assumed offering for fiscal year 2028 and has subsequently lowered its share count projections for fiscal year 2025, indicating financial constraints. These developments suggest a weak financial position that could impede the company's progress in developing its therapeutics.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares